Sector News

Lilly CEO Sees Light After a Difficult Year

October 20, 2014
Life sciences
Eli Lilly & Co. is deep into what Chief Executive John C. Lechleiter calls the “toughest year” in the drug maker’s 138-year history. Revenue at Lilly has plunged because of generic competition that followed patent expirations for several of its top-selling drugs, including the antidepressant Cymbalta.
 
The 61-year-old Dr. Lechleiter, meanwhile, faced one of his own toughest years in 2013: He took a two-month medical leave to undergo and recover from surgery to repair a damaged aorta.
 
Dr. Lechleiter, who joined Lilly as a chemist in 1979 and took over as CEO in 2008, says both he and Lilly are on the mend. The company has received regulatory approval to sell three new drugs—two for diabetes and one for gastric cancer—and has more experimental drugs in late-stage clinical testing.
 
In an interview at company headquarters in Indianapolis, the CEO talked about challenges facing Lilly and the health-care industry, including his desire for corporate tax reforms, and the impact of the Affordable Care Act on pharmaceutical makers. 
 
> Read the interview on the Wall Street Journal website
 
By Peter Loftus
 

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]